Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news